You are here:Home-Chemical Inhibitors & Agonists-Nuclear Receptor/Transcription Factor-ROR-RORγt agonist 8-074
RORγt agonist 8-074

Chemical Structure : RORγt agonist 8-074

CAS No.: 2211060-52-3

RORγt agonist 8-074

Catalog No.: PC-49473Not For Human Use, Lab Use Only.

RORγt agonist 8-074 is a potent, selective RORγt agonist with Kd of 497 nM, shows potent RORγt agonist activity in the Gal4 reporter gene assay with EC50 of 118.7 nM, and EC50 of 19.95 nM in FRET assays.

Packing Price Stock Quantity
100 mg Get quote
250 mg Get quote
500 mg Get quote
1 g Get quote

Bulk size, bulk discount!

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

Purity & Documentation Purity: >98% (HPLC)

Biological Activity

RORγt agonist 8-074 is a potent, selective RORγt agonist with Kd of 497 nM, shows potent RORγt agonist activity in the Gal4 reporter gene assay with EC50 of 118.7 nM, and EC50 of 19.95 nM in FRET assays.
RORγt agonist 8-074 displayed high selectivity versus the other two ROR members.
RORγt agonist 8-074 demonstrates stimulating the mouse Tc17 cells with EC50 at 11.21 nM.
RORγt agonist 8-074 demonstrated potent and selective binding to the RORγt protein as well as potent in vitro activity compared with LYC-55716.
RORγt agonist 8-074 promoted the secretion of IL-17A by Th17 cells with EC50 of 22.78 nM.
RORγt agonist 8-074 (160 nM) significantly increased the percentage of CD4+ T and CD8+ T cells that express IL-17A (from 12.1% to 24.0% in CD4+ T and 22.9% to 50.4% in CD8+ T cells).
RORγt agonist 8-074 (50 mg/kg, i.p. injection, QD over two weeks) showed robust antitumor efficacy in syngeneic tumor models, and 8-074 improved the efficacy of anti‑PD‑1 therapy in murine lung cancer models.

Physicochemical Properties

M.Wt 528.590
Formula C28H27F3N2O3S
Appearance Solid
CAS No.
Storage
Solide Powder
-20°C 12 Months; 4°C 6 Months
In Solvent
-80°C 6 Months; -20°C 6 Months
Shipping
Solubility

10 mM in DMSO

Chemical Name/SMILES

N-(3'-cyano-4'-isobutyl-2-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide

References

1. Li Xia, et al. J Exp Clin Cancer Res. 2022 Apr 23;41(1):155.

Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright

Contact Us sales@probechem.com

Bulk Inquiry

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • *Additional Information:

Get Quote

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • Additional Information: